What Causes Death With Merkel Cell Carcinoma? Avelumab Treatment and Occupational Exposure Risks

General Health and Science Information: A Foundation for Understanding Merkel Cell Carcinoma

The legacy heritage of general health and science information has long provided the public with foundational knowledge about disease prevention, treatment options, and wellness strategies. This broad educational approach has been instrumental in raising awareness about various medical conditions, including rare cancers, and has helped individuals navigate complex healthcare landscapes. Within this context, discussions about Merkel cell carcinoma have typically focused on patient outcomes, symptom management, and survival statistics, often emphasizing the importance of early detection and multidisciplinary care. Transitioning from this general health perspective, a more specialized concern emerges regarding occupational exposure to certain pharmaceutical agents. Specifically, healthcare workers and laboratory personnel who handle immunotherapeutic drugs such as Avelumab may face unique risks that warrant careful examination.

From General Awareness to Occupational Exposure: The Need for Targeted Safety Protocols

While Avelumab has demonstrated efficacy in treating Merkel cell carcinoma, its administration and preparation involve potential exposure pathways that differ from typical patient-centered discussions. The question of what causes death in Merkel cell carcinoma patients thus takes on additional dimensions when considering the occupational context of those who manufacture, prepare, or administer this therapy. This pivot from general health education to occupational exposure concern highlights the need for targeted safety protocols and monitoring systems in environments where Avelumab is handled regularly.

Merkel Cell Carcinoma: Disease Characteristics and Mortality

Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). It carries a poor prognosis, and in metastatic disease, immune checkpoint inhibition has significantly improved treatment outcomes, with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Death in patients with Merkel cell carcinoma can result from the disease itself or from complications of treatment. The aggressive nature of MCC means that progression of the malignancy—through local invasion, metastasis to vital organs, or systemic effects—is a primary cause of mortality.

Avelumab: Mechanism, Efficacy, and Immune-Related Adverse Events

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against PD-L1, functioning as an immune checkpoint inhibitor, and is approved in the USA, the EU, and Japan for the treatment of metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was the first therapeutic agent specifically approved for this indication, based on the phase II JAVELIN Merkel 200 trial, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). While the drug can induce durable responses, it also carries risks of immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs can be severe and, in rare instances, contribute to fatal outcomes.

Fulminant Type 1 Diabetes: A Rare but Life-Threatening irAE

One documented irAE associated with avelumab is fulminant type 1 diabetes. A case report describes an 81-year-old woman with no history of diabetes who developed this condition after 10 courses of avelumab for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/30738003/). She presented with elevated plasma glucose (483 mg/dL), hemoglobin A1c (7.5%), and ketosis, without prior hyperglycemic symptoms, and was diagnosed with insulin depletion (https://pubmed.ncbi.nlm.nih.gov/30738003/). Fulminant type 1 diabetes can lead to diabetic ketoacidosis, a life-threatening metabolic emergency that, if untreated, can cause death. This adverse effect highlights the need for monitoring blood glucose during avelumab therapy.

Hypercalcemia Due to Sarcoidosis Reactivation: Another Serious irAE

Another reported irAE is hypercalcemia due to reactivation of sarcoidosis during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). In this case, hypercalcemia was managed with corticosteroids and resolved fully, allowing continuation of avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, severe hypercalcemia can cause cardiac arrhythmias, renal failure, and neurological impairment, potentially leading to death if not promptly treated. The case underscores that avelumab can unmask or exacerbate underlying granulomatous diseases.

Limited Options After Avelumab Failure and Mortality Risk

For patients who become refractory to avelumab, treatment options are limited. In Europe, avelumab is the only approved systemic therapy for metastatic MCC, and for avelumab-refractory patients, efficient and safe alternatives are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). A retrospective study of five patients at three German sites who received combined ipilimumab and nivolumab after avelumab failure found that three responded per RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). This suggests that switching to another immune checkpoint inhibitor combination may offer benefit, but the small sample size limits generalizability. The lack of robust second-line options means that disease progression after avelumab failure can lead to death from MCC.

Adequacy of Warnings and Need for Vigilance

The prescribing information for avelumab includes warnings about immune-mediated adverse reactions, including endocrinopathies like type 1 diabetes and inflammatory conditions like sarcoidosis. However, the fulminant nature of diabetes onset, as reported, may not be fully anticipated by clinicians or patients, and the timeline—occurring after 10 cycles—indicates a need for sustained vigilance. Similarly, hypercalcemia due to sarcoidosis reactivation is a rare but serious event that requires awareness. Symptom-related considerations for affected patients include monitoring for signs of hyperglycemia (e.g., polyuria, polydipsia, weight loss) and hypercalcemia (e.g., nausea, vomiting, confusion, constipation). Because these symptoms can be nonspecific or absent until advanced, routine laboratory testing is essential.

Timeline of Harm and Summary of Mortality Causes

The timeline between avelumab exposure and documented harm varies: fulminant diabetes developed after 10 cycles (approximately 10 months if given every 2 weeks), while hypercalcemia occurred during treatment but resolved with intervention. Disease progression leading to death can occur at any point, especially in avelumab-refractory cases. In summary, death in Merkel cell carcinoma patients treated with avelumab can arise from the cancer itself or from treatment-related irAEs such as fulminant type 1 diabetes or hypercalcemia due to sarcoidosis. Adequate warnings exist but require emphasis on the need for ongoing monitoring. The aggressive nature of MCC and limited options after avelumab failure further contribute to mortality risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the primary cause of death in Merkel cell carcinoma patients?

Death in Merkel cell carcinoma patients can result from the disease itself—through local invasion, metastasis to vital organs, or systemic effects—or from complications of treatment, such as immune-related adverse events from therapies like avelumab.

Can avelumab treatment cause fatal side effects?

Yes, avelumab can cause severe immune-related adverse events, including fulminant type 1 diabetes leading to diabetic ketoacidosis and hypercalcemia due to sarcoidosis reactivation, which can be life-threatening if not promptly treated.

How common is fulminant type 1 diabetes with avelumab?

Fulminant type 1 diabetes is a rare but documented adverse event. A case report describes an 81-year-old woman who developed it after 10 courses of avelumab for metastatic Merkel cell carcinoma (https://pubmed.ncbi.nlm.nih.gov/30738003/).

What should healthcare workers handling avelumab be aware of?

Healthcare workers should be aware of potential occupational exposure risks and the need for monitoring patients for immune-related adverse events, including blood glucose and calcium levels, as well as signs of disease progression.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.